This podcast episode discusses the FDA's recent rejection of Lykos's MDMA application for PTSD treatment. The conversation explores the FDA's key concerns, including the need for more long-term data and research on drug interactions. The hosts delve into challenges like designing effective placebo trials, the role of personalized medicine, and the importance of understanding individual variations in treatment response. They also examine safety considerations, ethical concerns, and the future potential of MDMA-assisted therapy in mental health care.